The DOI matches its Crossref record; 29 of the 33 references it cites were found in a registry or an index.
Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study [RETRACTED]
Open accessAbstract
Hepatocellular carcinoma (HCC) is one of the most common neoplasms encountered, and its incidence is increasing worldwide. In this study, we explored the characteristics of gut microbiota in patients with primary hepatocellular carcinoma in advanced stage who received immune checkpoint inhibitors (ICIs) based on a large population with hepatitis B virus infection. An initial cohort of 65 patients with metastatic melanoma were included in this study. All patients were treated with ICIs at Fujian provincial geriatric hospital between August 2016 and June 2018. The 16S rDNA V4 region was amplified by Polymerase chain reaction and sequenced on the MiSeq platform. We found that the diversities of the gut microbiota in HCC who received ICIs were obviously increased. Negative feedback, which is controlled by interplay between microbial metabolic activities and host pathways, is thought to promote high bacterial diversity. We focused on the Faecalibacterium genus in response group, and Bacteroidales order in non-response group, and stratified patients into high versus low categories based on the median relative abundance of these taxa in the gut microbiome. Patients with high Faecalibacterium abundance had a significantly prolonged PFS versus those with a low abundance. Conversely, patients with a high abundance of Bacteroidales had a shortened progressive free survival compared to those with a low abundance. In summary, the present study examined the oral and gut microbiome of HCC patients undergoing immune checkpoint inhibitors immunotherapy. Significant differences were observed in the diversity and composition of the patient gut microbiome of responders versus non-responders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Baseline enrichment of F. prausnitzii in stools was found as a predictor of response to ICI in hepatocellular carcinoma14 and in NSCLC.15”
From Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors (2024) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,102 · cited 1×
“During recent years, new immune-modulatory agents were introduced for oncological treatment, eventually leading to the clinical breakthrough of checkpoint inhibitors (CPIs) targeting programmed death-1 (PD-1), programmed death-ligand 1 (PDL1), or cytotoxic T lymphocyte antigen-4 (CTLA-4).([8,9]) Therapies targeting th…”
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Duffy, A. G., Ulahannan, S. V., Makorova-Rusher, O., Rahma, O., Wedemeyer, H., Pratt, D., Davis, J. L., Hughes, M. S., Heller, T., ElGindi, M., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.10.029 · Cited by 819
Ponziani, F. R., Bhoori, S., Castelli, C., Putignani, L., Rivoltini, L., Del Chierico, F., Sanguinetti, M., Morelli, D., Paroni Sterbini, F., Petito, V., et al. (2019) · Hepatology · doi:10.1002/hep.30036 · Cited by 654 · cited 1×
“Moreover, correlations between the gut microbiota and liver cirrhosis (LC) were also characterized by metagenomics analysis.([23,24]) Tremendous advances have been made in the treatment of melanoma and other cancers using immune checkpoint inhibitors”
Koyama, M., Mukhopadhyay, P., Schuster, I. S., Henden, A. S., Hülsdünker, J., Varelias, A., Vetizou, M., Kuns, R. D., Robb, R. J., Zhang, P., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.011 · Cited by 254 · cited 1×
“The interaction between LPS and toll-like receptor 4 (TLR4) is crucial in the initiation and promotion of hepatocarcinogenesis through inflammation, chronic liver injury, and fibrosis.([15,16]) This complex proinflammatory network triggered by gut microbes involves resident liver cells and bone marrow-derived mononucl…”
Intestinal microbiota and its association with colon cancer and red/processed meat consumption
Abu‐Ghazaleh, N., Chua, W. J., & Gopalan, V. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15042 · Cited by 169 · cited 1×
“Increased intestinal permeability, which is a hallmark of cirrhosis, exposes the liver to a great amounts of bacteria and bacterial components,([13,14]) such as lipopolysaccharide (LPS), derived from the gut.”
Patel, S. S., Weirather, J. L., Lipschitz, M., Lako, A., Chen, P.-H., Griffin, G. K., Armand, P. A., Shipp, M. A., & Rodig, S. J. (2019) · Blood · doi:10.1182/blood.2019002206 · Cited by 146
Llópiz, D., Ruiz, M., Villanueva, L., Iglesias, T., Silva, L., Egea, J., Lasarte, J. J., Pivette, P., Trochon-Joseph, V., Vasseur, B., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2283-0 · Cited by 141
Ni, J., Huang, R., Zhou, H., Xu, X., Li, Y., Cao, P., Zhong, K., Ge, M., Chen, X., Hou, B., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01458 · Cited by 123
Brown, Z. J., Yu, S. J., Heinrich, B., Ma, C., Fu, Q., Sandhu, M., Agdashian, D., Zhang, Q., Korangy, F., & Greten, T. F. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2190-4 · Cited by 122
Chiang, C., Chan, A. C. Y., Chiu, K. W.-H., & Kong, F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01157 · Cited by 114
Cited by
Faecalibacterium: a bacterial genus with promising human health applications
Martín, R., Rios-Covian, D., Huillet, E., Auger, S., Khazaal, S., Bermúdez-Humarán, L. G., Sokol, H., Chatel, J.-M., & Langella, P. (2023) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuad039 · Cited by 566
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Crosstalk between Gut Microbiota and Host Immunity: Impact on Inflammation and Immunotherapy
Campbell, C., Kandalgaonkar, M. R., Golonka, R. M., Yeoh, B. S., Vijay-Kumar, M., & Saha, P. (2023) · Biomedicines · doi:10.3390/biomedicines11020294 · Cited by 243
“In addition, anti-PD-1 treatment for liver cancer patients resulted in elevated Faecalibacterium abundance and better progression-free survival [398].”
BackgroundBiomarkers of response to PD-1 pathway blockade
Li, H., van der Merwe, P. A., & Sivakumar, S. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01743-4 · Cited by 183
Critical role of the gut microbiota in immune responses and cancer immunotherapy
Li, Z., Xiong, W., Liang, Z., Wang, J., Zeng, Z., Kołat, D., Li, X., Zhou, D., Xu, X., & Zhao, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01541-w · Cited by 176
“Although multiple studies have demonstrated that better ICI efficacy in HCC patients appears to be correlated with a favorable gut microbiota [210–212], one recent study failed to confirm such a positive association in patients with HCC [213].”
Result
Metadata
- Authors
- LI, L., & Ye, J.
- Affiliations
- Fujian Provincial Hospital (CN)
- Corresponding author
- Ye, Jiajian
- ORCID
- Venue
- Medicine
- Published
- 2020-09-11
- Volume
- 99
- Issue
- 37
- Pages
- e21788
- ISSN
- 0025-7974 (ISSN-L)
- 1536-5964
- PMC
- PMC7489660
- OpenAlex
- W3085638664
- Cited by
- 57
- References
- 33
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 9 · 2023: 15 · 2022: 8 · 2021: 8 · 2020: 1
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- gold
- doi.org
- Licence
- Locations
- Medicine (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- hepatocellular carcinoma, gut microbiota, immune checkpoint inhibitors, immunotherapy response, Faecalibacterium, Bacteroidales, bacterial diversity, hepatitis B virus, oral microbiota, progression-free survival, metastatic melanoma
- MeSH terms
- Gastrointestinal Microbiome, Faecalibacterium, Progression-Free Survival, Aged, Bacteroides, China, Female, Carcinoma, Hepatocellular, Humans, Immunologic Factors, Immunotherapy, Liver Neoplasms, Male, Middle Aged, Prospective Studies, RNA, Ribosomal, 16S, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study [RETRACTED]. https://app.cochat.ai/papers/10.1097/md.0000000000021788
- The paper
- LI, L., & Ye, J. (2020). Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study [RETRACTED]. Medicine. https://doi.org/10.1097/md.0000000000021788
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.